Yu dɔktɔ dɔn tɛl yu ɔ sɔmbɔdi na yu famili fɔ bigin tek wan mɛrɛsin we de mek yu nɔ gɛt aromatase? Na nɔmal tin fɔ mek yu fred smɔl ɛn want fɔ no mɔ we yu yɛri dat. "Us kayn mɛrɛsin dis?", "Wetin mek dɛn de gi mi dis?", "Wetin go apin to mi?", "Ɛni sayd ɛfɛkt go de?" I go mɔs bi se yu gɛt bɔku kwɛstyɔn dɛn na yu maynd. So nɔ fred. Tide, wi go tɔk bɔt dis mɛrɛsin we dɛn kɔl aromatase inhibitor insay rili simpul langwej we yu kin ɔndastand, lɛk se yu de tɔk to yu padi.
Wetin na Aromatase Inhibitor (AI) insay simpul wɔd dɛn?
Fɔ tɔk am simpul wan, Aromatase Inhibitor na wan kayn ɔmon tritmɛnt we dɛn kin yuz fɔ kansa. Dɛn kin yuz dɛn mɔ fɔ trit wan kayn bɔdi kansa we dɛn kɔl Estrogen Receptor-Positive (ER+) .
Naw yu go mɔs de wɔnda, "Wetin dis `ER+` min?" I min sɔntin lɛk dis. Sɔm brɔst kansa sɛl dɛn kin ɛp fɔ gro ɛn skata bay wan ɔmon we dɛn kɔl ɛstrojen na wi bɔdi. jכs lεk aw plant nid wata εn fεtilayza fכ gro, dεn kεnsar sεl dεm ya de yuz di כmon εstrojen as dεn "fud." so, di kεnsar dεm we dis כmon εstrojen de mek dεn stimulate na dεn wi kכl `ER+` kεnsar dεm.
wetin wan Aromatase Inhibitor de du na fכ stכp di kεnsar sεl dεm fכ gεt da "fud" de. I de du dis bay we i: Wi bɔdi gɛt wan ɛnzaym we dɛn kɔl Aromatase . dis εnzym de kכnvכlt כda כmon dεm na di bכdi to εstrojen. So wetin dis mεdisin de du na fכ blok di akshכn fכ di Aromatase εnzym. afta dat di bכdi in prodakshכn fכ εstrojen de dכn bכku bכku wan. we εstrojen dכn, di kεnsar sεl dεm de lכs di "fud" we dεn nid fכ gro, εn dεn de day sכmtεm.
Fɔ tɔk am simpul wan, wan Aromatase Inhibitor de mek di kansa sɛl dɛn angri ɛn i de stɔp dɛn fɔ gro.
Dis tritmɛnt kin wok mɔ fɔ uman dɛn we dɔn pas 50 ia we dɔn go tru mɛnɔpos , bikɔs afta we uman dɔn pas 40 ia, di ɛstrojen na uman in bɔdi kin kɔmɔt mɔ tru dis aromatase ɛnzaym.
Uskayn kes dɛn kin gi dis tritmɛnt?
Bɔku tin dɛn de we dɔktɔ dɛn kin tɛl yu fɔ tek Aromatase Inhibitor tritmɛnt. Lɛ wi tek wan luk pan wetin dɛn bi.
- Afta dɛn dɔn ɔpreshɔn fɔ ER+ brɔst kansa: Dɛn kin gi dis mɛrɛsin fɔ mek di kansa nɔ kam bak, dat na fɔ ridyus di risk fɔ mek i kam bak.
- If di kansa dɔn skata to di limf no dɛm we de nia am: Dis tritmɛnt de ɛp fɔ kɔntrol di kansa we de skata mɔ.
- If di kansa dɔn spre (metastatic) to ɔda ɔgan dɛn na di bɔdi:Sɔntɛnde, bɔdi kansa kin pas to ɔda pat dɛn we de fa lɛk di lɔng, bon, bren, ɔ liva. Dɛn kin yuz dis tritmɛnt bak pan dɛn kayn tin ya.
- if yu gεt ER+ brεst kεnsar bifo yu mεnopos: Bikɔs di ovaria dεm stil de prodyuz εstrojen na dis ej, yu go nid fכ tek wan aromatase inhibitor wit כda tritmεnt dεm we de stכp di ovaria fכ prodyuz εstrojen.
- If yu gɛt bɔku risk fɔ gɛt `ER+` brɔst kansa: Sɔm stɔdi dɔn sho se dɛn mɛrɛsin ya de ridyus di risk fɔ gɛt bɔdi kansa. Bɔt dɛn nɔ ɔfishal wan gri fɔ du dis yet.
- If man gɛt `ER+` brɔst kansa: Yɛs, man dɛn kin gɛt bɔdi kansa bak. Dɛn kin gɛt smɔl smɔl ɔmon we dɛn kɔl ɛstrojen bak na dɛn bɔdi. So, tɛm kin de we dɛn kin gi man dɛnsɛf dis tritmɛnt.
Wetin na di kayn Aromatase Inhibitors we dɛn kin yuz mɔ?
Bɔku kayn mɛrɛsin ya de na di makit. Yu dɔktɔ go tɛl yu di wan we fit yu pas ɔl. Dis na di tri kayn dɛn we dɛn kin yuz mɔ.
| Jɛnɛrik Nem fɔ di Mɛdisin |
|---|
| Letrozole we dɛn kɔl |
| Anastrozol we dɛn kɔl |
| Exemestane we dɛn kɔl Exemestane |
Aw a go yuz dis mɛrɛsin? Aw lɔng a fɔ tek am?
Aromatase inhibitors na wan kayn pil we yu kin tek ɛvride . Dɛn kin gi yu dis mɛrɛsin we yu fɔs bigin fɔ trit yu. Ɔ, sɔm tɛm dɛn, yu dɔktɔ kin fɔs gi yu ɔda ɔmon tritmɛnt we dɛn kɔl tamoxifen fɔ sɔm ia ɛn afta dat i kin chenj yu to wan aromatase inhibitor.
Bɔku tɛm, dɛn kin kɔntinyu fɔ du dis tritmɛnt fɔ lɛk fayv ia so . We fayv ia dɔn, if yu nɔ gɛt ɛni sayn fɔ gɛt kansa ɛn tɛst sho se yu nɔ gɛt kansa, dɛn kin tek yu se yu de na rɛmishɔn.
Bɔt sɔntin de we impɔtant fɔ mɛmba. Sɔm stɔdi dɔn sho se bɔdi kansa kin kam bak as lɔng as 20 ia afta dɛn dɔn trit am. Dɛn kɔl dis let rikɔreshɔn . So e fayn fɔ tɔk to yu dɔktɔ bɔt dis risk, bay aw yu de si yu.
Wetin na di bɛnifit ɛn prɔblɛm dɛn we dis tritmɛnt de gi?
Jɔs lɛk ɛni tritmɛnt, bɛnifit ɛn risk de fɔ sɔm sayd ɛfɛkt dɛn.
Di men bɛnifit we pɔsin kin gɛt
di big εn imכtant advantej fכ dis tritmεnt na di chans fכ pul `ER+` brεst kεnsar kכmplit wan. Stɔdi dɔn sho se 95% pan di pipul dɛm wae gɛt dis tritmɛnt afta dɛn dɔn ɔpreshɔn dɛn nɔ go gɛt ɛni sayn fɔ kansa atɔl afta fayv ia. Dis na rili ay sakrifays rɛt.
Sɔm sayd ɛfɛkt dɛn we pɔsin kin gɛt (risks) .
As wi bin dɔn tɔk, dis mɛrɛsin de wok bay we i de ridyus di lɛvɛl we di ɛstrojen de na di bɔdi. Ɛstrojen na ɔmon we impɔtant fɔ mek uman bɔn pikin ɛn fɔ mek di bon ɛn at gɛt wɛlbɔdi . So we di ɛstrojen lɛvɛl go dɔŋ, sɔm sayd ɛfɛkt dɛn kin de we gɛt fɔ du wit am.
| Sayd Ifɛkt we i kin gɛt | Wan simpul ɛksplen |
|---|---|
| Ostioporosis ɛn fraktrɔs | As di εstrojen lεvεl de dכn, di bon dεm nכ de strכng bכku εn bigin fכ tan, we de mek di risk fכ brok ivin if yu fכl sכmtεm. |
| Mɔsul pen (Myalgia) ɛn jɔyn pen | Dis na wan sayd ɛfɛkt we kin rili kɔmɔn. Yu kin gɛt pen na yu jɔyn ɛn yu mɔsul dɛn kin shek shek na say dɛn lɛk yu an, yu leg, ɛn yu bak. |
| Hot flash dɛn we de shayn | Wantɛm wantɛm yu kin fil wam ɛn swet na yu fes, nɛk, ɛn chɛst. Dis tan lɛk wan sayn we pɔsin kin si we i dɔn lɛf fɔ gɛt bɛlɛ. |
| Di vagina dray we de dray | we di εstrojen lεvεl dכn dכn kin mek di vagina dεm dכn dכn, dray, εn i kin mek i nכ fil fayn. |
| Di sik we de ambɔg di at ɛn di blɔd | Bikɔs ɛstrojen de gi sɔm prɔtɛkshɔn bak fɔ di at wɛlbɔdi, we i de dɔŋ, i kin mek di risk fɔ gɛt at sik smɔl smɔl fɔ lɔng tɛm. |
Wetin yu kin du if yu gɛt prɔblɛm wit di bad tin dɛn we kin apin to yu?
Dɛn sayd ɛfɛkt ya, mɔ di joyn pen, kin so bad dat sɔm pipul dɛn nɔ kin ebul fɔ du tin dɛn we dɛn kin du ɛvride. Bɔt yu nɔ nid fɔ sɔfa we yu nɔ tɔk natin . Sɔlv dɛn de fɔ sɔlv di prɔblɛm. De tin wae impɔtant pas ɔl na fɔ tɔk opin wan wit yu dɔktɔ bɔt ɛni diskɔmfɔt wae yu de fil. I kin ɛp yu.
Yu dɔktɔ kin tɛl yu fɔ du tin dɛn lɛk:
- Anti-inflammatory medications: Dɛn kin gi non-steroidal anti-inflammatory drugs (NSAID) lɛk ibuprofen fɔ ridyus pen. Bɔt dɛn fɔ tek dɛn tin ya ɔnda dɔktɔ advays nɔmɔ.
- Switch to difrɛn Aromatase Inhibitor: Sɔntɛnde di sayd ifɛkt dɛm fɔ wan kayn AI nɔ kin apin wit ɔda kayn. So yu dɔktɔ kin tɛl yu fɔ tray difrɛn AI pil.
- Fɔ chenj to Tamoxifen: If di sayd ɛfɛkt dɛn nɔ go ebul fɔ bia, i kin bi se yu go ebul fɔ chenj to ɔda ɔmon tritmɛnt we dɛn kɔl Tamoxifen.
Ustɛm yu fɔ kɔl di dɔktɔ?
Mek shɔ se yu tɔk to yu dɔktɔ pan dɛn kayn tin ya:
- If di sayd ɛfɛkt dɛn bad pas aw yu bin de tink ɛn i nɔ izi fɔ bia wit.
- If di mɛrɛsin we di dɔktɔ gi nɔ ɛp wit di sayd ɛfɛkt dɛm.
- If yu notis ɛni chenj na yu bɔdi we yu sɔspɛkt se kin bi sayn fɔ kansa we de kam bak (e.g. nyu lump, pen we nɔ kɔmɔn). (Ask yu dɔktɔ us sayn dɛm fɔ luk fɔ).
Aw impɔtant dis tritmɛnt?
Aromatase inhibitor tεrapi de ridyus di risk fכ hכmon-positiv brεst kεnsar fכ kam bak bכku bכku wan. Stɔdi dɔn sho se uman dɛn we de tek aromatase inhibitor therapy afta dɛn dɔn ɔpreshɔn dɛn kin gɛt 40% smɔl risk fɔ day wit brɔst kansa afta 10 ia, we yu kɔmpia am wit di wan dɛn we nɔ de tek ɛni ɔmon tɛrapi.
Wan ɔda stɔdi dɔn sho se if yu tek di mɛrɛsin `Letrozole' i kin ridyus di risk fɔ day wit kansa bay 24% to 35% .
Dɛn statystik ya de sho aw dis tritmɛnt impɔtant fɔ sev yu layf. Yu kin want fɔ stɔp dis tritmɛnt bikɔs ɔf di sayd ɛfɛkt dɛm. Bɔt bifo yu du dat, i go fayn fɔ mek yu tɔk to yu dɔktɔ bɔt dɛn tin ya we kin mek yu nɔ fil fayn, kɔntrol dɛn, ɛn tray fɔ dɔn dis tritmɛnt we go sev yu layf.
Mɛsej we dɛn kin kɛr go na os
- Aromatase Inhibitors (AI) na wan rili ifektiv ɔmon tritmɛnt fɔ ER+ brɔst kansa, mɔ afta we yu dɔn menɔpauz.
- Dis kin mek di ɔmon we de na di bɔdi we gɛt ɛstrojen nɔ bɔku, i kin mek di kansa sɛl dɛn nɔ gro, ɛn i kin mek di kansa nɔ kam bak bad bad wan.
- Sayd ɛfɛkt lɛk aw yu jɔyn dɛn kin pen ɛn yu bon dɛn kin wik, bɔt we dɛn de fɔ kɔntrol dɛn. Nɔ ɛva sɔfa we yu nɔ tɔk natin; tɔk to yu dɔktɔ ɔltɛm.
- Fɔ mek yu gɛt maksimal rizɔlt ɛn fɔ mek di kansa nɔ kam bak, i rili impɔtant fɔ tek di mɛrɛsin lɛk aw dɛn tɛl yu fɔ tek am, bɔku tɛm fɔ fayv ia.
- Notis yu dɔktɔ wantɛm wantɛm if yu gɛt ɛni nyu ɔr we de wɔs na yu bɔdi.
💬 Comments (0)
No kɔmɛnt nɔ de yet. Ad yu kɔmɛnt ya fɔ di fɔs tɛm.
Ad yu kɔmɛnt